| __timestamp | Alnylam Pharmaceuticals, Inc. | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 9079000 |
| Thursday, January 1, 2015 | 60610000 | 20309000 |
| Friday, January 1, 2016 | 89354000 | 16945000 |
| Sunday, January 1, 2017 | 199365000 | 20559000 |
| Monday, January 1, 2018 | 382359000 | 29641000 |
| Tuesday, January 1, 2019 | 479005000 | 88258000 |
| Wednesday, January 1, 2020 | 588420000 | 162170000 |
| Friday, January 1, 2021 | 620639000 | 167218000 |
| Saturday, January 1, 2022 | 770658000 | 239528000 |
| Sunday, January 1, 2023 | 795646000 | 94252000 |
| Monday, January 1, 2024 | 975526000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Alnylam Pharmaceuticals, Inc. and Galapagos NV, two prominent players in the industry, have shown contrasting strategies over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Galapagos NV maintained a more conservative approach, with a 940% increase, indicating a focus on cost efficiency.
By 2023, Alnylam's SG&A expenses were approximately eight times higher than those of Galapagos, highlighting its commitment to scaling operations. However, Galapagos's steady growth in expenses suggests a strategic balance between cost management and business development. This comparison offers valuable insights into how biotech companies can navigate financial strategies to optimize their operational efficiency.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Alnylam Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Mesoblast Limited
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Galapagos NV
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
SG&A Efficiency Analysis: Comparing Opthea Limited and Galapagos NV
Selling, General, and Administrative Costs: Verona Pharma plc vs Galapagos NV